| [1] |
DingY，ChoiME.Autophagy in diabetic nephropathy [J]. J Endocrinol, 2015，224(1)：R15-R30.
|
| [2] |
ZarzynskaJM .The importance of autophagy regulation in breast cancer development and treatment[J]．Biomed Res Int，2014，2014：710345.
|
| [3] |
NagataE,SaiardiA,TsukamotoH，et al. Inositol hexakisphosphate kinases promote autophagy[J]. Int J Biochem Cell Biol, 2010 , 42(12)：2065-2071.
|
| [4] |
MaycotteP，ThorburnA．Targeting autophagy in breast cancer[J]. World J Clin Oncol, 2014 , 5(3)：224-240.
|
| [5] |
ChenS,RehmanSK,ZhangW，et al. Autophagy is a therapeutic target in anticancer drug resistance[J]. Biochim Biophys Acta，2010，1806(2)：220-229.
|
| [6] |
HouG,YangS,ZhouY, et al. Targeted inhibition of mTOR signaling improves sensitivity of esophageal squamous cell carcinoma cells to cisplatin[J]. J Immunol Res，2014，2014：845763.
|
| [7] |
NishikawaT,TakaokaM,OharaT, et al. Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice[J]. Cancer Biol Ther，2013，14(3)：230-236.
|
| [8] |
OngCA,ShannonNB,Ross-InnesCS, et al. Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy[J]. JNCI J Natl Cancer Inst，2014，106(5) pii: dju050.
|
| [9] |
PaplomataE,O'ReganR. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers[J]. Ther Adv Med Oncol，2014，6(4)：154-166.
|
| [10] |
ZhongY,WangQJ,LiX，et al. Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin1- phosphatidylinositol 3-kinase complex[J]. Nat Cell Biol, 2009，11(4): 468-476.
|
| [11] |
KoukourakisMI,GiatromanolakiA，SivridisE, et al. Beclin1 over- and underexpression in colorectal cancer: distinct patterns relate to prognosis and tumour hypoxia[J]. Br J Cancer, 2010，103(8)：1209-1214.
|
| [12] |
RoeslyHB,KhanMR,ChenHD，et al. The decreased expression of Beclin-1 correlates with progression to esophageal adenocarcinoma: the role of deoxycholic acid[J]. Am J Physiol Gastrointest Liver Physiol，2012，302(8)：G864-G872.
|
| [13] |
WangTT,CaoQH,ChenMY, et al. Beclin1 deficiency correlated with lymph node metastasis, predicts a distinct outcome in intrahepatic and extrahepatic cholangiocarcinoma[J]. PLoS One, 2013，8(11)：e80317.
|
| [14] |
GuoGF,JiangWQ, et al. Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer[J]. World J Gastroenterol, 2011，17(43)：4779-4786.
|
| [15] |
ChenZ,LiY,ZhangC, et al. Downregulation of Beclin1 and impairment of autophagy in a small population of colorectal cancer[J]. Dig Dis Sci, 2013，58(10)：2887-2894.
|
| [16] |
GengQR,XuDZ,HeLJ, et al. Beclin-1 expression is a significant predictor of survival in patients with lymph node-positive gastric cancer[J]. PLoS One, 2012, 7(9)：e45968.
|
| [17] |
SakuraiT,OkumuraH,MatsumotoM，et al. The expression of LC-3 is related to tumor suppression through angiogenesis in esophageal cancer[J]. Med Oncol，2013，30(4)：701.
|
| [18] |
HaoCL,LiY,YangHX，et al. High level of microtubule-associated protein light chain 3 predicts poor prognosis in resectable esophageal squamous cell carcinoma[J]. Int J Clin Exp Pathol，2014，7(7)：4213-4221.
|
| [19] |
WangBS,YangY,YangH, et al. PKCι counteracts oxidative stress by regulating Hsc70 in an esophageal cancer cell line[J]. Cell Stress Chaperones, 2013，18(3)：359-366.
|
| [20] |
LiouGY,StorzP. Reactive oxygen species in cancer[J]. Free Radic Res，2010，44(5)：479-496.
|
| [21] |
BrownNS,BicknellR. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer[J]. Breast Cancer Res，2001，3(5)：323-327.
|
| [22] |
TongM,ChanKW,BaoJY, et al. Rab25 is a tumor suppressor gene with antiangiogenic and anti-invasive activities in esophageal squamous cell carcinoma[J]. Cancer Res, 2012, 72(22)：6024-6035.
|
| [23] |
XuX,GuanX,TaoH, et al. An association study on genetic polymorphisms of Rab37 gene with the risk of esophageal squamous cell carcinoma in a Chinese Han population[J]. Int J Med Sci，2013，10(3)：235-242.
|
| [24] |
ShiGZ,YuanY,JiangGJ, et al. PRAF3 induces apoptosis and inhibits migration and invasion in human esophageal squamous cell carcinoma[J]. BMC Cancer，2012，12：97.
|
| [25] |
GarciaCJ,Castro-CombsJ,DiasA，et al. Insulin/insulin-like growth factor-1 pathway in Barrett’s carcinogenesis[J]．Clin Transl Gastroenterol，2013，4：e40.
|
| [26] |
WangY,DingQ,YenCJ, et al. MC: The crosstalk of mTOR/S6K1 and Hedgehog pathways[J]. Cancer Cell，2012, 21(3)：374-387.
|
| [27] |
KimmelmanAC. The dynamic nature of autophagy in cancer[J]. Genes Dev，2011，25(19)：1999-2010.
|
| [28] |
LuJ,SunD,GaoS, et al. Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells[J]. J Pharmacol Sci，2014，125(1)：74-82.
|
| [29] |
KenificCM,ThorburnA,DebnathJ. Autophagy and metastasis: another double-edged sword[J]. Curr Opin Cell Biol，2010，22(2)：241-245.
|
| [30] |
ChoiKS. Autophagy and cancer[J]. Exp Mol Med，2012，44(2)：109-120.
|
| [31] |
ChenN,KarantzaV. Autophagy as a therapeutic target in cancer[J]. Cancer Biol Ther, 2011, 11：157-68.
|
| [32] |
ZhaoZ,OhS,LiD, et al. A dual role for UVRAG in maintaining chromosomal stability independent ofautophagy[J]. Dev Cell，2012，22(5)：1001-1016.
|
| [33] |
HaoQ,ChoWC. Battle against cancer: an everlasting saga of p53[J]. Int J Mol Sci, 2014，15(12)：22109-22127.
|
| [34] |
RingerL,SirajuddinP,TricoliL, et al. The induction of the p53 tumor suppressor protein bridges the apoptoticand autophagic signaling pathways to regulate cell death in prostate cancercells[J]. Oncotarget, 2014，5(21)：10678-10691.
|
| [35] |
RabinowitzJD,WhiteE. Autophagy and metabolism[J]. Science，2010，330: 1344-1348.
|
| [36] |
PortaC,PaglinoC,MoscaA. Targeting PI3K/Akt/mTOR Signaling in Cancer[J]. Front Oncol.，2014, 4: 64.
|
| [37] |
MorranDC,WuJ,JamiesonNB, et al. Targeting mTOR dependency in pancreatic cancer[J]. Gut. 2014. 63(9): 1481-1489.
|
| [38] |
O'DonovanTR,O'SullivanGC,McKennaSL. Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics[J]. Autophagy，2011，7(5)：509-524.
|
| [39] |
ChengC,VerstovsekS,CancerLett. The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells[J]. Cancer Lett，2010，293(2)：167-174.
|
| [40] |
DuffyA,LeJ,SausvilleE, et al. Autophagy modulation: a target for cancer treatment development[J]. Cancer Chemother Pharmacol, 2015，75(3)：439-447.
|
| [41] |
YardleyDA,NoguchiS,PritchardKI, et al. Everolimus plus exemestane in postmenopausal patients with HR(＋) breast cancer: BOLERO-2 final progression-free survival analysis[J]. Adv Ther, 2013，30(10)：870-884.
|
| [42] |
OceanAJ,ChristosP,SparanoJA, et al. Phase Ⅱ trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach[J]. Invest New Drugs, 2014，32(3)：542-548.
|
| [43] |
MaHB,DiZL,WenJ, et al. Prospective, open, multicentre Phase Ⅰ/Ⅱ trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma[J]. Jpn J Clin Oncol, 2015，45(2)：169-175.
|